Cronos Group SEC Filings

Cronos Group Inc. officer Adam Wagner reported routine equity compensation activity. On May 10, 2026, he exercised restricted stock units, converting 20,470 RSUs into the same number of common shares at no cash cost. Following these transactions, he directly owns 93,620 common shares. Footnotes explain these RSUs came from prior grants of 30,190 and 31,220 RSUs awarded in 2023 and 2024, each vesting in three substantially equal annual installments, so this filing reflects scheduled vesting rather than open‑market trading.

Cronos Group Inc. officer Jared Matthew Kenost reported routine equity compensation activity. On May 10, 2026, previously granted restricted stock units vested and were exercised into 12,649 common shares. To cover tax obligations, 4,774 common shares were disposed of at $2.54 per share as tax-withholding, not as open-market sales. Following these transactions, he continues to hold a direct equity stake in Cronos common shares.

Cronos Group Inc. reported significantly stronger results for the quarter ended March 31, 2026. Net revenue rose to 45,210 (thousands of U.S. dollars) from 32,262 a year earlier, driven by cannabis flower and extracts in Canada and Israel. Net income attributable to Cronos increased to 13,752, with basic and diluted EPS of 0.04 versus 0.02. Adjusted EBITDA improved to 5,079 from 2,289, reflecting higher gross profit despite ongoing restructuring and transaction costs. The company ended the quarter with 821,856 in cash and cash equivalents and no debt, after repurchasing 6,365,700 common shares for 16,730 under its 50,000 share repurchase authorization. A new 50,000 repurchase program was approved to follow the current one, and Cronos continues to pursue the pending acquisition of CanAdelaar and manage legal and regulatory matters, including a proposed 10,000 class action settlement that remains subject to court approval.

Cronos Group Inc. reported strong first quarter 2026 results, with net revenue rising 40% year-over-year to $45.2 million and net income more than doubling to $15.7 million. Adjusted EBITDA improved to $5.1 million, up 122% from the prior-year period, helped by higher cannabis flower and extract sales in Canada, Israel and other international markets.

The company’s Spinach, PEACE NATURALS, LIT and Lord Jones brands all contributed to growth, including #1 vape share in Canada and continued leadership in Israeli medical cannabis. Cronos ended the quarter with $821.9 million in cash and cash equivalents and authorized a new share repurchase program of up to $50 million running through May 2027. The company also extended the outside date to close its pending acquisition of Dutch producer CanAdelaar B.V. to September 9, 2026 to allow more time for regulatory clearances.

Cronos Group Inc. is holding its 2026 annual meeting of shareholders as a virtual-only event on June 18, 2026 at 11:00 a.m. Eastern time. Shareholders will vote on electing seven directors, advisory “say on pay” and its frequency, and appointing Davidson & Company LLP as independent auditor for 2026.

The meeting will also receive the audited consolidated financial statements for the year ended December 31, 2025. Shareholders of record at 5:00 p.m. Eastern time on April 23, 2026, when 376,271,333 common shares were outstanding, are entitled to vote online, by telephone, Internet or mail.

Cronos Group Inc. officer Anna Shlimak exercised restricted stock units that converted into 28,429 common shares on March 19, 2026. These RSUs represent the first vesting portion of an 85,297-unit grant awarded on March 19, 2025, scheduled to vest in three substantially equal annual installments.

To cover related tax obligations, 9,767 common shares were withheld and disposed of at a price of $2.54 per share. After these compensation-related transactions, Shlimak directly holds 358,595 common shares of Cronos Group Inc., with no remaining derivative position reported in this filing.

Cronos Group Inc. officer Terrence Gregory Joseph Doucet exercised 23,897 restricted stock units into an equal number of common shares. These RSUs were part of a grant of 71,691 units awarded on March 15, 2023, vesting in three substantially equal annual installments.

To cover tax obligations related to the vesting, 12,276 common shares were withheld at a price of C$3.44 per share. After these transactions, Doucet directly holds 105,190 common shares and 184,408 restricted stock units, showing this was primarily a compensation-related vesting and tax-withholding event rather than an open-market trade.

Cronos Group Inc. officer Arye Weigensberg reported compensation-related equity transactions. On March 16, 2026, he received a grant of 12,245 restricted stock units (RSUs), each representing a right to receive one common share, vesting in three substantially equal annual installments beginning on the first anniversary of the grant date.

On March 15, 2026, he exercised 24,236 RSUs into an equal number of common shares, reflecting the vesting of part of an earlier RSU grant made on March 15, 2023. Following these transactions, he directly owns 208,437 common shares and holds 157,537 RSUs. These are grants and conversions, not open-market purchases or sales.

Cronos Group Inc. director and officer Michael Ryan Gorenstein exercised restricted stock units that converted into common shares as part of a prior equity award. He exercised 324,540 RSUs, each representing one common share, and received an equivalent number of common shares at a stated exercise price of $0.00 per share.

To satisfy tax obligations on this vesting event, 127,706 common shares were withheld at a value of $2.50 per share, leaving him with 13,213,017 common shares held directly after the transactions. Following the RSU exercise, his remaining restricted stock unit balance was 1,912,426 RSUs. These RSUs come from a 973,618-unit grant awarded on March 15, 2023, vesting in three annual installments.